Although the overall response rate among the cohort was 96.4%, this figure dropped as low as 66.7% when accounting for male gender, GT3 infection, cirrhosis, obesity, and non-response to previous therapy.
Pharmacists' expertise is crucial in educating patients about regulatory changes, helping them navigate alternative formulations, and providing insights into evidence-based choices.